IN8bio
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell IN8bio and other ETFs, options, and stocks.About INAB
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S.
CEOWilliam T. Ho
CEOWilliam T. Ho
Employees18
Employees18
HeadquartersNew York, New York
HeadquartersNew York, New York
Founded2016
Founded2016
Employees18
Employees18
INAB Key Statistics
Market cap8.78M
Market cap8.78M
Price-Earnings ratio-0.19
Price-Earnings ratio-0.19
Dividend yield—
Dividend yield—
Average volume62.35K
Average volume62.35K
High today$2.02
High today$2.02
Low today$1.93
Low today$1.93
Open price$1.97
Open price$1.97
Volume95.75K
Volume95.75K
52 Week high$12.53
52 Week high$12.53
52 Week low$1.91
52 Week low$1.91
INAB News
TipRanks 3d
IN8bio expands INB-100 Phase 1 trial with new clinical siteIN8bio (INAB) announced that The Ohio State University has been added as a new clinical site in the ongoing Phase 1 trial of the Company’s INB-100, a donor-deri...
TipRanks 5d
IN8bio Unveils Promising Preclinical Data for INB-619Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...
TipRanks 5d
IN8bio presents new preclinical data from INB-619IN8bio (INAB) presented new preclinical data from its gammadelta T cell engager program, INB-619, at the 2025 American College of Rheumatology, ACR, Convergence...
People also own
Based on the portfolios of people who own INAB. This list is generated using Robinhood data, and it’s not a recommendation.